III期非小细胞肺癌辅助度伐利尤单抗治疗时长的降阶梯
该回顾性队列研究纳入美国退伍军人事务系统2017年11月至2021年4月接受根治性放化疗及辅助度伐利尤单抗的1006例III期非小细胞肺癌患者,中位治疗时长7个月,31%完成计划疗程,早期停药最常见原因为肿瘤进展(22%)、免疫相关不良事件(15%)和非免疫相关毒性(6.0%);边缘结构模型提示9个月与12个月无进展生存相似,6个月较12个月无进展生存更差。
要点
- 中位度伐利尤单抗治疗时长7个月(四分位距2.8-11.5),仅31%完成计划疗程。
- 早期停药最常见原因为肿瘤进展(22%)、免疫相关不良事件(15%)、非免疫相关毒性(6.0%)。
- 边缘结构模型提示9个月与12个月无进展生存相似,6个月较12个月无进展生存更差。
核心结论
- 相当比例接受辅助度伐利尤单抗的患者因毒性早期停药,较短治疗时长可能提供与12个月相似的疾病控制。
- 需要前瞻性随机对照研究来明确局部晚期非小细胞肺癌患者的最佳度伐利尤单抗治疗时长。
研究设计与样本
- 回顾性队列研究,纳入美国退伍军人事务系统2017年11月至2021年4月接受根治性放化疗及至少一剂辅助度伐利尤单抗的III期非小细胞肺癌患者1006例。
- 采用Cox比例风险回归评估早期停用度伐利尤单抗的预测因素。
- 采用边缘结构模型和时间依赖Cox模型比较不同治疗时长(至多6、9、12个月)对无进展生存和总生存的影响。
主要发现
- 度伐利尤单抗中位治疗时长7个月(四分位距2.8-11.5),31%完成计划度伐利尤单抗疗程。
- 早期停药最常见原因为肿瘤进展(22%)、免疫相关不良事件(15%)和非免疫相关毒性(6.0%)。
- 边缘结构模型提示9个月与12个月度伐利尤单抗治疗的无进展生存相似。
- 边缘结构模型提示6个月较12个月度伐利尤单抗治疗的无进展生存更差。
局限性
- 需要前瞻性随机对照研究来明确局部晚期非小细胞肺癌患者的最佳度伐利尤单抗治疗时长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One year of adjuvant durvalumab following concurrent chemoradiotherapy significantly improves progression-free survival (PFS) and overall survival (OS) for patients with stage III non-small cell lung cancer (NSCLC). However, the optimal length of adjuvant therapy has not been determined. METHODS: We identified patients with stage III NSCLC treated with definitive chemoradiation and adjuvant durvalumab from November 2017 to April 2021 from the United States Veterans Affairs system. Predictors of early durvalumab discontinuation were evaluated with Cox proportional hazards regression. The effect of differing durations of durvalumab treatment (up to 6, 9, and 12 months) on PFS and OS were compared with a marginal structural model and time-dependent Cox modelling. RESULTS: We included 1006 patients with stage III non-small cell lung cancer who received concurrent chemoradiotherapy and at least one dose of adjuvant durvalumab. The median duration of durvalumab treatment was 7 months (interquartile range 2.8-11.5) and 31% completed the intended durvalumab course. The most common reasons for early discontinuation were tumour progression (22%), immune-related adverse events (15%), and non-immune-related toxicity (6.0%), Marginal structural models suggested similar PFS for 9 months versus 12 months of durvalumab treatment and inferior PFS for 6 months versus 12 months. CONCLUSIONS: A substantial proportion of patients undergoing adjuvant durvalumab discontinue therapy early due to toxicity, and shorter durvalumab treatment durations may provide similar disease control to 12 months of therapy. Prospective randomised controlled studies are needed to characterise the optimal durvalumab treatment duration in locally advanced NSCLC patients.
引用
- Bryant AK, Sankar K, Zhao L, et al. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. Eur J Cancer. 2022. PMID: 35704975. doi:10.1016/j.ejca.2022.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。